
Bispecific Antibody Therapy
This video gives a quick introduction to bispecific antibody therapy. Learn more about different treatment options for hemophilia with the
Year: 2016
Language: English
This resource is also available in: Arabic French Russian Spanish Simplified Chinese
Author(s): World Federation of Hemophilia
Format: Document
This resource has also been translated into the following languages, with permission from the WFH, by NMOs: Polish
Desmopressin (DDAVP) may be the treatment of choice for patients with mild or moderate hemophilia A and type 1 von Willebrand disease (VWD). This Fact Sheet presents essential information about this synthetic medicine which costs much less than plasma products or recombinant clotting factor concentrates, carries no risk of transmission of viral infections, and is on the World Health Organization’s (WHO) Model List of Essential Medicines (EML).

This video gives a quick introduction to bispecific antibody therapy. Learn more about different treatment options for hemophilia with the

This video gives a quick introduction to standard half-life (SHL) clotting factor replacement therapy. Learn more about different treatment options

This fact sheet contains commonly asked questions and more information on standard half-life (SHL) and extended half-life (EHL) clotting factor
In these sessions from the WFH 2022 World Congress, listen to Kate Khair, Luke Pembroke, Louis Marlow, Andrew Selvaggi, Robert

In this session from the WFH 2020 Virtual Summit, Glenn Pierce, Johnny Mahlangu, David Page & Brian O’Mahony explore the

In this session from the WFH 2020 Virtual Summit, Radoslaw Kaczmarek, Flora Peyvandi, Dan Hart & Johnny Mahlangu discuss novel